Lisa Barbera received her MD from the University of Ottawa in 1995. She completed her radiation oncology specialty training at the University of Toronto in 2000, and then completed a two-year fellowship in the Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute (formerly known as the Radiation Oncology Research Unit). Dr. Barbera holds Masters in Public Administration from the School of Policy Studies at Queen’s University.
Dr. Barbera joined ICES in February 2005 as an Adjunct Scientist. She is an Ontario Ministry of Health and Long-Term Care Career Scientist, a Scientist at the Sunnybrook Research Institute, and an Assistant Professor in the Department of Radiation Oncology at the University of Toronto.
Research interests include palliative care, quality indicators and patterns of cancer care.
Winson Y. Cheung, MD, MPH, FRCPC is a medical oncologist and a nationally and internationally recognized health services researcher. He is currently an Associate Professor of Medicine in the Department of Oncology at the University of Calgary where he is the Provincial Director of Health Services Research for Cancer Control Alberta. He is also an adjunct faculty member in the Department of Medicine at the University of British Columbia where he continues to advise on the academic and research curriculums of medical undergraduate programs across Canada.
Dr. Cheung received his medical degree at the University of British Columbia, medical oncology subspecialty training at the University of Toronto and subsequently obtained a Masters of Public Health degree at Harvard University. He specializes in the management of gastrointestinal malignancies. He is the recipient of numerous accolades, including the National Cancer Institute of Canada Dorothy Lamont Award, the Novartis Oncology Young Canadian Investigator Mentor Award, the Multinational Association of Supportive Care in Cancer Investigator Award, and several merit awards from the American Society of Clinical Oncology. He has secured over 5 million dollars in grant funding.
Dr. Cheung’s primary research interest is health services and outcomes research. His projects focus on understanding the interplay of various patient, physician, and system level factors that drive practice patterns in the real world setting and learning how processes can be modified to better inform care. The overarching goal of his work is to ensure that cancer care is appropriately accessed and delivered to patients. His own research and those of his trainees appear frequently in high impact scientific journals. To date, he has published over 100 peer-reviewed manuscripts. He takes great pride in mentoring students, residents, and junior staff, many of whom have successfully developed prolific academic careers.
Mary McBride is an epidemiologist, health services researcher, and Distinguished Research Scientist in the Cancer Control Research Department of the BC Cancer Agency. She is also Clinical Professor in the School of Population and Public Health and member of the Department of Pediatrics, University of British Columbia. Mary oversees two research programs investigating late effects and health care issues post-treatment for young people diagnosed with cancer, and women diagnosed with breast cancer, using research platforms developed by linking person-specific, longitudinal, population-based registries and clinical and administrative databases. She is also a co-investigator in a recently-funded CIHR Team Grant on gaps and coordination in oncology and primary care for cancer patients across the care trajectory, from pre-diagnosis to end-of-life. She has also led and contributed to research on the causes of childhood cancer, and the relationship between non-ionizing electromagnetic fields (ELF-EMF and RF) and cancer, in Canada, the US, Europe, and for the World Health Organization.
Morris L. Barer is a Professor and Co-Lead, Health Care Services and Systems, in the new School of Population and Public Health at the University of British Columbia (UBC). He also is (and was the founding) Director of the Centre for Health Services and Policy Research at UBC. From December 2000 to August 2006, he served as the first Scientific Director of the Institute of Health Services and Policy Research, Canadian Institutes of Health Research. During that time, he played leadership roles in the establishment of the Canadian Association for Health Services and Policy Research (CAHSPR), and the Canadian journal Healthcare Policy, first published in 2005.
Dr. Barer’s research interests include healthcare financing, health human resource policy (particularly physicians), direct-to-consumer advertising of prescription pharmaceuticals, and the determinants of changing trends in healthcare utilization.
Michael M. Burgess is Professor and Research Chair in Biomedical Ethics at the W. Maurice Young Centre for Applied Ethics in the Department of Medical Genetics at the University of British Columbia. His research has focused on health, science and technology policy and public engagement based on theories of deliberative democracy. With co-lead Kieran O’Doherty, the research team developed an approach to deliberative engagement on biotechnology policy, with eight events in BC, the Mayo Clinic and in western Australia across topics of biobanks, salmon genomics and environmental remediation. Recently, Dr. Burgess has begun to emphasize the wider social effects and policy implications of genomic and computational technologies often characterized as personalized medicine.
Jennifer Gibson is Interim Director of the University of Toronto Joint Centre for Bioethics and Associate Professor in the Institute of Health Policy, Management, & Evaluation at the University of Toronto. At ARCC, she leads the Societal Values & Public Engagement program with Dr. Stuart Peacock. Dr. Gibson has broad interdisciplinary research and policy experience in healthcare priority setting, organizational ethics in health institutions, and ethics in health policy. Gibson leads the WHO Collaborating Centre for Bioethics at the University of Toronto. and has served as an expert member on government advisory committees on policy issues related to critical care triage, drug funding and supply, organ transplantation, pandemic planning, citizen engagement, and health system integration.
Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative), the F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, Professor in the Faculties of Medicine and Pharmacy, University of Toronto, Senior Scientist the Toronto General Research Institute, and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. Dr. Krahn’s research program focuses on the use of decision analytic methods to examine health policy and health decision making. Recent research includes the development of clinical policy models, disease-specific utility instruments, and use of large administrative data sets for developing longitudinal cost models. He also is interested in methods that integrate competing scientific paradigms in the evaluation of new drugs and technologies.
Hsien Seow holds McMaster University’s Cancer Care Ontario Research Chair in Health Services Research in the Department of Oncology. His PhD is from Johns Hopkins School of Public Health, Department of Health Policy and Management, with a concentration in health services research and a certificate in Gerontology. His research interests involve examining ways to better coordinate, organize and deliver healthcare services and improve quality for those with serious, chronic illness. He has worked with RAND Health in Washington DC, where he led health policy research, quality improvement, and health advocacy initiatives. He earned a B.Sc from Yale University.
Jaclyn completed her BSc (Honours) in biology and her MSc in health services research at the University of Toronto. She works closely with policy-makers, clinicians and researchers to develop and evaluate pharmacoeconomic analyses for new cancer therapies. Her research interests include economic evaluation of cancer screening and treatment interventions with Markov models, the role of pharmacoeconomic evidence in reimbursement decision-making, and KTE for health economic methods and findings.
Sonya is a research scientist and her research interests lie in the appraisal of biomedical innovation, optimized public health and the efficient use of healthcare resources. She holds a Bachelor of Science from the University of Victoria, a PhD from the University of British Columbia and a Masters in Business Administration from Simon Fraser University.
Wanrudee Isaranuwatchai is a health economist and manager of the Centre for exceLlence in Economic Analysis Research (CLEAR). She received her PhD in Health Services Research from the Institute of Health Policy, Management and Evaluation at the University of Toronto. She also holds a Bachelor of Science in Health Studies and Gerontology from the University of Waterloo.
Dr. Isaranuwatchai has experience conducting economic evaluations using decision modeling and patient-level data. Her research interests include health economics, economic evaluations, cancer research, disaster, mental health, and quantitative research methods. Dr. Isaranuwatchai is committed to promoting the use of evidence in health care decision making.
Reka Pataky is a Health Economist and Data Lead with the Canadian Centre for Applied Research in Cancer Control, based at the BC Cancer Agency. Her work focuses on health services research using secondary analysis of administrative datasets, and economic evaluation of cancer control programs. She is currently involved in multi-provincial projects investigating the health system costs attributable to cancer and the quality of end-of-life cancer care. Previous work includes cost-effectiveness analysis of prostate cancer screening and breast cancer screening programs using decision modeling methods.
Reka holds an MSc from UBC’s School of Population and Public Health, conducting her thesis research with the UBC Centre for Health Services and Policy Research. She is currently pursuing her PhD under the supervision of Dr. Stuart Peacock, exploring the economic evaluation of personalized medicines in cancer.
Deirdre is a Health Economist with the Canadian Centre for Applied Research in Cancer Control (ARCC). Her work focuses on estimating the cost-effectiveness of personalized oncogenomics and applying discrete choice methods to elicit preferences for precision medicine in oncology. Her research interests include applied econometrics, health care policy, and health economics. Deirdre holds an MA in Economics from the University of Victoria and a BSc in Economics, Mathematics, and Statistics from the University of British Columbia. Prior work experience includes pharmaceutical policy research with the UBC Centre for Health Services and Policy Research.
Dr. Bansback’s research seeks to inform policies and practices in health through the application of health economics and decision theory. His methodological research in measuring and valuing health, economic evaluation and network meta-analysis have been applied to a wide range of applications from informing policy makers on resource allocations decisions, to patients making treatment choices. His ARCC funded research has focused on helping patients make better treatment choices through novel decision tools, and risk surveys.
Dr. Fillion is a Full Professor in Nursing Sciences at Laval University, Quebec City and an Adjunct Professor in Psychology at Montreal University, Montreal, Quebec. She is also a researcher at the Cancer Research Center at Laval University and a member of the Michel Sarrazin Psychosocial Oncology and Palliative Care Research Team (ERMOS). She is the scientific director of the CHUQ Nursing Research Unit (URSI-CHUQ), and a member of the CHUQ Research Center – cancer division steering committee (CRCHUQ-axe cancer). She works as a psychologist with the Psychosocial and Spiritual Oncology team at the CHUQ. She has received grants from the FRSQ (Fond de recherche en santé du Québec), the Canadian Cancer Society (CCS), the Canadian Cancer Society Research Institute (CCSRI), the Ministère de la Santé et des Services Sociaux (MSSS), the Canadian Health Services Research Foundation (CHSRF), the Canadian Institute of Health Research (CIHR), the Institut de recherche en santé et en sécurité au travail (IRSST), the ASSS-03, and the Canadian Partnership Against Cancer (CPAC). Dr. Fillion’s area of expertise is cancer survivorship and palliative care. More specifically, her interests include psychological stress, psychosocial adaptation to cancer, methodological aspect of the measurement of stress and of the adaptation to cancer, coping, symptoms management (stress, fatigue, pain), satisfaction and meaning at work in health care providers, models of care, and professional navigation in oncology.
Dr. Jennifer Jones is the Director of Research for the Cancer Survivorship Program, Associate Director of the Centre for Health Wellness and Cancer Survivorship (ELLICSR) and a Research Associate in the Department of Psychosocial Oncology and Palliative Care at Princess Margaret Hospital. In addition, she is an Assistant Professor in the Department of Psychiatry, at University of Toronto.
Dr. Jones’ research program has primarily focused on psychosocial factors among the medically ill. This has included the assessment of symptoms and quality of life at the end of life and the use of proxy assessments. More recently, through her work within the newly developed Cancer Survivorship Program at Princess Margaret Hospital (PMH),her research interests have included: 1) assessing the prevalence and impact of long-term and late effects of cancer and its treatment (i.e. fatigue, bone loss) and psychosocial distress in cancer survivors; 2) the development and evaluation of group and individual psychoeducational interventions to promote patient engagement in self-management activities and to support families affected by cancer; 3) evaluation of new innovative models of care delivery. She has also developed expertise in the area of continuing education and professional development and knowledge translation.
Dr. Marshall is an Associate Professor in the Department of Community Health Sciences, University of Calgary and the Director of Health Technology Assessment (HTA) at the Alberta Bone and Joint Health Institute and Associate Professor (part-time) in the Department of Clinical Epidemiology and Biostatistics at the Centre for Evaluation of Medicines at McMaster University. Her Canada Research Chair, Health Services and Systems Research is a HTA research programme involving synthesis of evidence, measurement of preferences, cost-effectiveness analysis, and decision modeling of health systems. Dr. Marshall has research experience in HTA agencies, academic institutions and industry settings in Canada, US and Europe. Dr. Marshall’s academic training includes a PhD from the School of Public Health at the University of North Carolina, Chapel Hill as an Alberta Heritage Foundation for Medical Research Scholar, an MSc in Health Services Research (University of Alberta) and a BSc in Biochemistry (University of Toronto).
Her peer-reviewed cancer research grants from the US National Institutes of Health / National Cancer Institute and the Ontario Institute for Cancer Research are focused in the areas of measuring patient preferences using conjoint analysis, personalized medicine, and cost-effectiveness modeling. She is a Project Leader of the Economics Project in the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS – clinicalpharmacy.ucsf.edu/transpers), dedicated to developing evidence-based information for patients and other stakeholders to objectively assess how personalized medicine can be most beneficial and efficient in improving health outcomes.
Dr. Marshall is an active member of the International Society for Pharmacoeconomics and Outcomes Research as a member of the Patient Preferences Special Interest Group and as President-Elect member of the Board of Directors. She was also a member of the CADTH/NCIC Working Group to develop cancer-specific economic evaluation guidelines, and the NCI Clinical Trials and Translational Research Advisory Board Cost-Effectiveness Analysis Working Group. She also serves on the editorial board of the International Journal for Technology Assessment in Health Care and The Patient.
Dr. Jason Pole is Scientist with the Pediatric Oncology Group of Ontario (POGO) and is an Assistant Professor in the Dalla Lana School of Public Health, University of Toronto and an Adjunct Scientist with the Hospital for Sick Children Research Institute and the Institute for Clinical Evaluative Sciences, Toronto. Jason has a background in epidemiology and health services research with an emphasis in the use of administrative data and complex survey instruments. Jason has research interests in the areas of health care utilization among childhood cancer survivors, the effects of childhood cancer treatment specifically on the development of second cancers and education achievement and has interests in the financial impact of a childhood cancer diagnosis on the family and the long-term financial health of the survivor.
Dr. Wranik is a health economist, whose research is focused on three broad topics, all related to efficient and evidence supported health policies and health policy decisions. The first of the three topics is the improved understanding of decision making processes in the approval of services or drugs for public funding, and specifically the actual and potential role played by economic evidence. The second is an aggregate assessment of health system efficiencies using frontier methods, along with an investigation into the policy tools that are associated with more efficient systems. The third is a focus on physician payments as one of the policy levers that can be used to improve efficiencies in the system.
Since 2006, Dr. Wranik has served as a health economist on the Nova Scotia Systemic Cancer Therapy Committee, which offers advice to the Minister with respect to the funding of new cancer drugs and therapies. Her work consists of the analysis and interpretation of economic evidence that is provided by the industry in support of their submissions. It is here where Dr. Wranik’s interest was sparked in the misalignment of the use and the production of cost-utility analyses. She has identified a need for a framework for decision making processes that gives clear guidance to both health economists and decision makers.
Dr. Wranik teaches graduate courses in health economics, managerial economics and program evaluation at the School of Public Administration at Dalhousie University.
Sarah Benn was the previous Network Manager for the Canadian Centre for Applied Research in Cancer Control (ARCC). Sarah brought to ARCC strong communication and relationship-building skills, from her experience working with a number of interdisciplinary and inter-professional groups. Sarah received her Master of Arts degree in Health and Aging from McMaster University. She also holds a Bachelor of Arts, Honours Sociology from Bishop’s University.
Stirling Bryan is Director of the Centre for Clinical Epidemiology & Evaluation, and full professor in the School of Population & Public Health at UBC. He is also honorary professor at the University of Birmingham (UK), an Associate of the UBC Centre for Health Services & Policy Research and an Adjunct Associate at the Center for Health Policy at Stanford University. In 2005/06 Stirling was a Commonwealth Fund Harkness Fellow in Health Care Policy, based at Stanford. He sits on the UK Medical Research Council’s College of Experts, the Scientific Committee of the International Health Economics Association and the Editorial Board of Health Economics, a journal for which he is also an Associate Editor. Dr Bryan’s research interests span the areas of economic evaluation and health technology assessment from applied and methodological perspectives, including preference elicitation and outcome measurement, and the use of economic analyses in decision-making. England.
Dilfuza is a research assistant and is studying the use of an incremental cost-effectiveness threshold in health sector decision-making and the use a net benefit regression approach in the economic evaluation of health care technologies. Dilfuza’s responsibilities include collecting, summarizing and analyzing data related to these projects. Her previous work experience was focused on research and teaching methodology. She received her PhD from the Tashkent State University of Pedagogy in Uzbekistan.
Mark Elwood is an epidemiologist and public health medicine specialist. He is Vice-President of Family and Community Oncology at the British Columbia Cancer Agency, and a Clinical Professor at the University of British Columbia. He has previously worked in Australia, New Zealand and the UK.
Dr. Elwood is involved in cancer control strategies including new approaches to early diagnosis and screening for oral, colorectal and lung cancers and for melanoma, and in epidemiological research and the use of scientific knowledge in policy development. Along with Dr. Simon Sutcliffe, he has edited a book on Cancer Control, to be published by Oxford University Press (England) early in 2010.
Richard Gallagher is Head, Cancer Control Research Program at the BC Cancer Agency, and Clinical Professor, School of Population and Public Health at the University of BC, in Vancouver, Canada. He is an associate member of the Departments of Dermatology and Skin Sciences, and Urologic Sciences, and a Fellow of the American College of Epidemiology.
Research interests are in environmental epidemiology, with emphasis on cohort studies, UV radiation and skin cancers, and risk factors for prostate cancer. He is the principal investigator of the BC component (BC Generations Project) of the Canadian Partnership for Tomorrow, a national prospective cohort under construction as a platform for population-based disease research for scientists across Canada.
Richard serves on the Board of Directors of the National Cancer Institute of Canada and the Board of Directors of the Canadian Cancer Society. In 2007 he received the BCMAs Terry Fox Medal for Cancer Research, and in 2008 an honorary PhD from the DSPT in Berkeley, California. He is author of more than 200 scientific papers and numerous book chapters.
As a research scientist Lindsay is responsible for conducting cost-effectiveness studies evaluating specific cancer care interventions. Much of this work is currently focused on colorectal cancer screening and treatments. She is an active member of the steering and evaluation committees for Colon Check, BC′s pilot colorectal cancer screening program. Lindsay is also working towards PhD in health services and systems in the School of Population and Public Health at UBC. Previous work experience focused on studying the service utilization patterns of survivors of childhood cancer at the BC Cancer Agency. In general, her research interests include national and provincial health care policies as they pertain to primary health care, priority setting and resource allocation methodologies and applications, and health technology assessment.
David C. Hodgson is an Associate Professor and clinician scientist in the Department of Radiation Oncology, and the Department of Health Policy, Management and Evaluation at the University of Toronto. He is a staff radiation oncologist at the Princess Margaret Hospital, and an Adjunct Scientist at the Institute for Clinical Evaluative Sciences in Toronto.
He received his medical degree and radiation oncology training at the University of Toronto and a Masters degree in Public Health from Harvard University.
Dr. Hodgson’s research activities include technology assessment and the use of population-based health administrative data to evaluate the treatment and outcome of cancer patients. He has received peer-reviewed funding from the Canadian Institutes for Health Research, the National Cancer Institute of Canada and Cancer Care Ontario.
Louis Lemieux-Charles is Chair of the Department of Health Policy, Management and Evaluation (HPME), University of Toronto. She also is an Associate Professor in HPME, Program Director of the Hospital Management Research Unit, an adjunct scientist with the Institute for Work and Health, and a member of the Collaborative Centre for Bioethics at the University. Previously, she held positions in senior management in the acute care system, in teaching and in consulting. She is actively involved in both the MHSc and the MSc/PhD programs as teacher, preceptor and thesis supervisor.
Dr. Lemieux-Charles’s research focuses on performance management, human resources management, organizational learning, knowledge transfer and service delivery networks – all within the context of healthcare. Some of her ongoing research projects involve the relationship of performance indicators to an organization’s strategic performance; the role of evidence in major system change; and the effectiveness of community-based networks in the delivery of care to individuals with dementia and their caregivers.
Steve Morgan is an Associate Professor in the University of British Columbia’s (UBC) School of Population and Public Health, and an Associate Director of the UBC Centre for Health Services and Policy Research. He has published over 100 articles and reports on pharmaceutical policy issues, and has served as an advisor to governments across Canada and abroad.
The unifying theme of Dr. Morgan’s work is the pursuit of policies that achieve balance between three sometimes competing goals: providing equitable access to necessary care, managing health expenditures, and promoting valued innovation.
As a research scientist Syed is conducting research on childhood cancer in Canada and in developing countries. Currently he is involved in developing international collaborative research on childhood cancer in developing countries, social stigma attached to cancer and public participation in priority setting decision-making process. He has over 20 years’ experiences in health and social research, and health policy analysis. He has expertise in conducting research using both qualitative and quantitative methodologies.
His previous work experience in the London School of Hygiene and Tropical Medicine, University of London, UK focused on health system development, health care financing, and health human resources in low and middle income countries. His other research interests include national and provincial health care policies as they pertain to primary health care, priority setting and resource allocation methodologies and applications, and health technology assessment. Syed has PhD in Health Economies and Health Service Research from the University of London, UK and Masters in Health Management, Planning and Policy from the University of Leeds, UK.
Dr. Sullivan is the former President and Chief Executive Officer of Cancer Care Ontario, a position he occupied for 10 years. From 1993 to 2001, Dr. Sullivan held the position of President of the Institute for Work & Health — a private, not-for-profit Institute affiliated with the University of Toronto, which he developed into North America’s leading research centre on work-related injury. Dr. Sullivan has held senior roles in the Ontario ministries of Health, and Intergovernmental Affairs, and in the Cabinet Office. He served two successive First Ministers of Ontario as Executive Director of the Premier’s Council on Health Strategy, including a period of time as Deputy Minister.
Dr. Sullivan is an active behavioral scientist with research and practice interests in cancer prevention and health system performance.
He holds faculty appointments in the Departments of Health Policy, Management and Evaluation and Public Health Sciences at the University of Toronto. His current voluntary commitments include acting as Vice-Chair of the Ontario Agency for Health Protection and Promotion. Previous Board experience includes the Canadian Partnership Against Cancer, the Canadian Association of Provincial Cancer Agencies, the Ontario Institute for Cancer Research, AllerGen’s Institute for Clinical Evaluative Sciences, and the University Health Network.
Kerynn Wang completed her MPH at the University of Hong Kong and holds an HBSc from the University of Toronto. As a Research Associate with the Cancer Services and Policy Research Unit, Kerynn is assisting the team on various service-directed research projects that examines strategic policy issues to support cancer system decision-makers and broader health policy researchers. Previous work experience focused on exploring the inter-relationships within health services multidisciplinary research teams and analyzing health system interventions. Her research interests include evidence-based impact evaluation in applied health services, as well as strategies to facilitate knowledge exchange within the cancer and health policy systems.
Dr. Baukje (Bo) Miedema is professor of Family Medicine and Director of Research at the Dalhousie University Family Medicine Teaching Unit in Fredericton. She has trained as a general and psychiatric nurse in Holland before she earned her PhD in Sociology at the University of New Brunswick. Over the years she has developed a robust program of research in cancer survivorship including cancer follow-up care and rehabilitation issues. Bo has received provincial, regional and national grants (CIHR & SSHRC) as principal investigator and as co-investigator to support her research endeavors. She has published extensively with more than 50 peer reviewed papers and three books as author or editor. She has strong working relationships nationally and internationally by being involved in various professional organizations related to cancer in primary care. Bo is a non-physician member of the College of Family Physicians of Canada and has served as a member of the Section of Researchers of the College. Further, she serves as a reviewer for many national and international journals and granting agencies. In her spare time she is President of the Board of Directors of the Multicultural Association of Fredericton (MCAF). MCAF provides a broad range of services to the newcomer community in Fredericton and has a workforce of around 50 part-time and full-time employees.
Ross Duncan is a Health Economist; his research considers trends in health-care utilization and costs associated with cancer survivorship.